This site is intended for healthcare professionals only
News
Share this article

Lower blood pressure enhances SGLT2 renoprotection

By Colin Kenny, Editor – Diabetes Distilled

Researchers wanted to understand the relationship between the renoprotective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors and blood pressure (BP) in patients with low BP. They examined BP and urinary albumin:creatinine ratio data from patients with type 2 diabetes and chronic kidney disease before and after treatment. Lower BP was found to be associated with greater change in urinary albumin:creatinine ratio following treatment with SGLT2 inhibitors. The researchers concluded that stricter BP management is required to enhance the renoprotective effects of SGLT2 inhibitors.

BP control is important in the management of people with diabetes, particularly those with chronic kidney disease. Japanese investigators performed a retrospective study on 740 patients to investigate the renal effects of SGLT2 inhibitors in patients with low BP and determine the overall effects of BP management on the clinical outcomes of treatment. Patients were split into two groups based on their BP management status at the time SGLT2 inhibitor treatment was started. There were 327 patients with well controlled BP (<130/80 mmHg) and 413 with poorly controlled BP (systolic BP >130 mmHg or diastolic BP >80 mmHg). 
 
When the two groups were compared following treatment, the well-controlled BP group had a greater reduction in albumin:creatine ratio than the poorly controlled BP group. This finding confirms that BP management status after SGLT2 inhibitor administration influences the extent of urinary albumin:creatinine ratio change.

Stricter BP management might be needed in general practice to enhance the renoprotective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. 


To access the publication, click here

Related content
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.